Major Scope

  •  Colon and Rectal Surgery
  •  General Surgery
  •  Gynecologic Oncology
  •  Plastic Surgery
  •  Neurological Surgery
  •  Orthopaedic Surgery
  •  Orthopaedic Surgery of the Spine
  •  Neonatal Surgery
  •  Prenatal Surgery
  •  Trauma Surgery
  •  Surgical Intensivists, Specializing In Critical Care Patients
  •  Thoracic Surgery
  •  Congenital Cardiac Surgery
  •  Thoracic Surgery-Integrated
  •  Vascular Surgery

Abstract

Citation: Clin Surg. 2020;5(1):2772.Research Article | Open Access

Molecular Profiling Use in Patients with Resectable versus Unresectable Metastatic Colorectal Cancer

Nkem J Nweze1*, Ashlie Nadler2, Elizabeth Handorf2, Biao Luo2 and Jeffrey M Farma2

1Department of Surgery, Einstein Healthcare Network, USA
2Department of Surgical Oncology, Fox Chase Cancer Center, USA

*Correspondance to: Nkem J Nweze 

 PDF  Full Text DOI: 10.25107/2474-1647.2772

Abstract

Background: The effect of molecular profiling on clinical treatment practices in metastatic colorectal cancer remains to be elucidated. Materials and Methods: Retrospective cohort study using a tertiary referral cancer hospital clinical database (March 2006 to August 2016). Metastatic colorectal cancer patients who underwent molecular profiling were identified and divided into 2 groups: Primary Resectable vs. Primary Unresectable. Tumor molecular profile data, clinical treatments rendered and overall survival were analyzed and compared. Results: Median time from diagnosis of metastatic disease to molecular profiling was 7.7 months in the Primary Resectable group vs. 2 months in the Primary Unresectable group. Two or three mutations were detected in 58% of patients. KRAS was the most common actionable mutation. Among the KRAS mutated patients with known treatment, 59% received bevacizumab. KRAS wild type was present in 52% of patients, and 19% of this group received cetuximab or panitumumab. BRAF was mutated in 5% of our cohort, and a targeted therapy was used in 5% of this group. Median time from initial cancer diagnosis to molecular profiling was 12.2 months overall, 29.9 months in the Primary Resectable Group, and 2 months in the Primary Unresectable Group (p<0.001). Median survival time was 4.7 years overall, 5.7 years in the Primary Resectable Group, and 2.7 years in the Primary Unresectable group (p<0.001). Conclusion: There was use of a targeted therapy based on KRAS mutations identified by molecular profiling. Further research is necessary to correlate molecular profiling data, targeted therapy use and clinical trial accrual with survival outcomes in metastatic colorectal cancer patients.

Keywords

Molecular profiling; Colorectal cancer; Targeted therapy

Cite the article

Nweze NJ, Nadler A, Handorf E, Luo B, Farma JM. Molecular Profiling Use in Patients with Resectable versus Unresectable Metastatic Colorectal Cancer. Clin Surg. 2020; 5: 2772..

Journal Basic Info

  • Impact Factor: 2.395**
  • H-Index: 8
  • ISSN: 2474-1647
  • DOI: 10.25107/2474-1647
  • NLM ID: 101702548

Search Our Journal

Journal Indexed In

Articles in PubMed

Mesh Sprayer Device with Liquefied Mesh Delivery System: Proposed Alternative for Currently Available Meshes in Hernia Repair and Supplement to Abdominal Closure
 PubMed  PMC  PDF  Full Text
Automated Sagittal Craniosynostosis Classification from CT Images Using Transfer Learning
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Therapeutic Embolization for Treating Erectile Dysfunction Secondary to Priapism: A Case Report
 Abstract  PDF  Full Text
Preoperative Intra-Aortic Balloon Pump Inserted in Acute Myocardial Infarction Patients without Cardiogenic Shock Undergoing Surgical Coronary Revascularization
 Abstract  PDF  Full Text
View More...